Printer Friendly

Research and Markets: Common Drug Review Tracker 2008 Annual Report - Premier Package.

DUBLIN -- Research and Markets ( has announced the addition of the "Common Drug Review Tracker 2008 Annual Report - Premier Package" report to their offering.

The CDR Tracker 2008 Annual Report a provides a year-over-year analysis of the activities of Canada's Common Drug Review and public drug plans in Canada from 2003 to 2008.

Wyatt Health Management has been publishing information about the Common Drug Review (CDR) and public drug plans in Canada since the inception of CDR in 2003 through the CDR Tracker. The CDR Tracker Annual Report provides an overview of the Common Drug Review plus year-over-year comparisons of selected information.

The CDR Tracker reviews recommendations made by the Canadian Expert Drug Advisory Committee (CEDAC), the decision-making body of the Common Drug Review. CDR Tracker also reports the reimbursement decisions of the public drug plans on all the drugs that have been involved in the CDR process. The CDR Tracker continues to evolve by adding information requested by member subscribers.

CDR Tracker focuses on the major public drug plans including all participating provincial drug plans, the Quebec drug plan, which does not participate in the CDR process, plus three major federal public drug plans (Non-Insured Health Benefits - NIHB, which serves the Canada's native population; Veterans' Affairs Canada - VAC, which serves veterans of foreign conflicts and peacekeeping; and the Department of National Defence - DND, which serves current members of the Canadian armed forces). CDR Tracker Annual Report does not provide detailed information on the VAC or DND activities because these plans serve distinct audiences.

By the end of 2008, the Common Drug Review had reviewed and made recommendations on one hundred and twenty-one (121) submissions. Members asked us to develop a publication that would provide an overview of the CDR process and a year-by-year analysis. The CDR Tracker Annual Report was born. This is the first edition.

The CDR Tracker2008 Annual Report is an excellent report for those in senior management who want a comprehensive, yet concise, overview of Canada's Common Drug Review (CDR).

The CDR Tracker 2008 Annual Report provides a year-over-year analysis of the activities of Canada's Common Drug Review and public drug plans in Canada. The premier package provides year over year comparisons from 2003 to 2008 PLUS 26 ready to use Power Point slides

Products Mentioned

* All CDR Reviewed Drugs from 2003

Companies Mentioned

* All companies who have had products reviewed by the CDR.

Key Topics Covered:

* About CDR Tracker

* History of the Common Drug Review (CDR)

* Committees

* Submissions to Canada's Common Drug Review (CDR)

* CEDAC Recommendations

* Overall: Yes vs. No

* Overall: Analysis of "Yes"

* Drug Categories: "Mainstream" and Biologics

* "Mainstream" Drugs: Yes vs. No

* Biologic Drugs: Yes vs. No

* Key CDR Timelines

* NOC to CDR Submission

* CDR Submission to CEDAC Recommendation

* Public Plan Reimbursement

* Time to Listing - TTL

* TTL: Notice of Compliance (NOC) to Listing

* TTL: CEDAC Recommendation to Listing

* CDR Tracker Annual Report - Scorecard 2008

* Common Drug Review

* Public Drug Plans

* The Canadian Ranking Picture

* Summary

* Appendix 1: CDR Developments - 2008

For more information visit
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 20, 2009
Previous Article:Report That Nonprofit Leadership Gap Grew 43% Sparks "Call to Action" by Sector Stakeholders.
Next Article:SolarWinds IPO Creates Opportunity for PacketTrap MSP.

Related Articles
CADTH launches first-ever podcasts/audio summaries of HTA reports.
Animal TB 'tracker' created to speed up drug and vaccine studies.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters